Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety and immunogenicity study of Ag85B-ESAT-6 tuberculosis subunit vaccine with CAF01 adjuvant
NL-OMON33959Phase 1Active, not recruiting
- Sponsor
- Statens Serum Institut
- Start
- Nov 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ag85B-ESAT-6 and CAF01 in Tuberculosis (TB) (4 arms), sponsored by Statens Serum Institut. Primary endpoints: Adverse reactions and Safety laboratory changes. Started Nov 2009; status: active, not recruiting.
02
Drugs
Ag85B-ESAT-6CAF01
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NL-OMON33959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33959.